Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 May 5;59(5):2102921.
doi: 10.1183/13993003.02921-2021. Print 2022 May.

Inhaled corticosteroids for outpatients with COVID-19: a meta-analysis

Todd C Lee  1   2   3 , Émilie Bortolussi-Courval  3 , Sara Belga  4 , Nick Daneman  5 , Adrienne K Chan  5 , Ryan Hanula  3 , Nicole Ezer  6   7 , Emily G McDonald  2   3   8   7
Affiliations
Meta-Analysis

Inhaled corticosteroids for outpatients with COVID-19: a meta-analysis

Todd C Lee et al. Eur Respir J. .

Abstract

The role of inhaled corticosteroids for outpatient COVID-19 is evolving. Meta-analysis of reported clinical trials estimated probability of any effect for symptom resolution by day 14 at 100% and hospitalisation at 89.3%, respectively. https://bit.ly/3B2sDUi

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: T.C. Lee reports grants or contracts from Fonds de Recherche Quebec – Sante, Canadian Institutes of Health Research, and McGill Interdisciplinary Institute Infection and Immunity, outside the submitted work. S. Belga reports grants or contracts from Vancouver Coastal Health Research Institute and Transplant Research Foundation of BC, outside the submitted work. E.G. McDonald reports that the study drug for the CONTAIN trial, which is one study in this meta-analysis, was donated to our team by COVIS pharmaceuticals. N. Ezer reports grants or contracts from Fonds de Recherche du Québec en Santé, Rossy Cancer Network, Canadian Institute of Health Research, and MEDTEQ, outside the submitted work; consulting fees were received from GlaxoSmithKline and AstraZeneca, outside the submitted work; receipt of equipment, materials, drugs, medical writing, gifts or other services from COVIS Pharma (study drug donation for CONTAIN trial; unrestricted). The remaining authors have nothing to disclose.

References

    1. Ramakrishnan S, Nicolau DV, Langford B, et al. . Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med 2021; 9: 763–772. doi:10.1016/S2213-2600(21)00160-0 - DOI - PMC - PubMed
    1. Yu L-M, Bafadhel M, Dorward J, et al. . Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet 2021; 398: 843–855. doi:10.1016/S0140-6736(21)01744-X - DOI - PMC - PubMed
    1. Wechsler ME, Kelley JM, Boyd IOE, et al. . Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med 2011; 365: 119–126. doi:10.1056/NEJMoa1103319 - DOI - PMC - PubMed
    1. Ezer N, Belga S, Daneman N, et al. . Inhaled and intranasal ciclesonide for the treatment of Covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. BMJ 2021; 375: e068060. - PMC - PubMed
    1. Clemency BM, Varughese R, Gonzalez-Rojas Y, et al. . Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: a randomized clinical trial. JAMA Internal Medicine 2022; 182: 42–49.10.1001/jamainternmed.2021.6759 - DOI - PMC - PubMed

Substances